|
|
|
|
|
State-Of-The-Industry Videos By Leading Urology Experts
|
|
|
|
|
|
|
Advances in PSMA-directed Radionuclide Therapy - Howard Soule
|
| Howard Soule discusses highlights and his takeaways from the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. Dr. Soule highlights the importance of coming to these conferences to understand where the gaps are in the treatment landscape and the benefit of these global conferences for clinicians from resource-limited countries
|
|
|
|
|
|
|
|
|
|
|
|
The Risk of Dose De-intensifying Treatment, Bone Health in Prostate Cancer - Fred Saad
|
| Alicia Morgans and Fred Saad have a discussion on bone health in prostate cancer patients, an issue for men with advanced prostate cancer and an important topic to keep at the forefront of care.
|
|
|
|
|
|
|
|
|
|
|
|
A Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer - The VISION Trial, Interview with Oliver Sartor
|
| Oliver Sartor joins Charles Ryan to talk about the VISION trial, a trial testing the PSMA-617 agent, The novel therapeutic drug 177Lu-PSMA-617 is a prostate-specific membrane antigen (PSMA) targeting agent to deliver radionuclide therapy for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
|
|
|
|
|
|
|
|
|
|
|
|
Guiding First Line Treatment Decisions for mCRPC After ADT + Docetaxel or AR Pathway Inhibitor - Mary-Ellen Taplin
|
| Mary-Ellen Taplin joins Alicia Morgans to share highlights from her 2019 Advanced Prostate Cancer Consensus Conference (APCCC) presentation on first line treatment of metastatic castration-resistant prostate cancer (mCRPC) after patients have received either docetaxel or abiraterone, enzalutamide, or apalutamide and the lack of data to guide treating physicians in this treatment setting.
|
|
|
|
|
|
|
|
|
|
|
|
The Side Effects of Advanced Prostate Cancer Consensus Conference 2019 (APCCC) - Silke Gillessen and Aurelius Omlin
|
| In advanced prostate cancer, rapid and successful drug development has resulted in multiple treatment options that require careful decision-making for individual patients. Clinicians face the increasingly difficult task of choosing from multiple potentially effective treatments that also are costly and potentially toxic.
|
|
|
|
|
|
|
|
|
|
|
| How Best to Treat cN1 Prostate Cancer - Karim Fizazi
|
| Karim Fizazi, MD, Ph.D
|
| Karim Fizazi summarizes how best to treat node-positive (cN+) prostate cancer patients at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). There are over 20 randomized controlled trials in localized and advanced prostate cancer that have been published according to Dr. Fizazi, yet he notes, none have been published in the setting of node-positive prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
|
| Report and Lessons Learned From The Consensus Conference For Developing Countries Presentation - Fernando Maluf
|
| Fernando Maluf, MD
|
| In this presentation by Fernando Maluf at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC) he summarizes the results of the first Latin American Oncology Group (LACOG) consensus conference, a Cooperative Group Consensus that takes place in Brazil, a consensus conference for developing countries.
|
|
|
|
|
|
|
|
|
|
|
|
| Clinical Utility of Molecular Biomarkers Presentation - Johann de Bono
|
| Johann de Bono, MB ChB FRCP MSc Ph.D. FMedSci
|
| Professor de Bono presents the clinical utility of predictive molecular biomarkers in advanced prostate cancer during the first session of the Advanced Prostate Cancer Consensus Conference (APCCC 2019).
|
|
|
|
|
|
|
|
|
|
|
|
| Management of Men With PSA Recurrence or Persistence After Prostatectomy
|
| Christopher Evans, MD, FACS
|
| Christopher Evans discussed the management of men with PSA recurrence or persistence after radical prostatectomy during the Advanced Prostate Cancer Consensus Conference 2019, session on PSA recurrence after radical local therapy and oligometastatic prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
|
| Treatment of Oligometastatic and Oligoprogressive CRPC Presentation - Eric Small
|
| Eric J. Small, MD
|
| Eric Small presents on the treatment of oligometastatic and oligoprogressive castration-resistant prostate cancer (CRPC) at the Advanced Prostate Cancer Consensus Conference (APCCC 2019).
|
|
|
|
|
|
|
|
|
|
|
|
| PARP Inhibition for Metastatic Castration-Resistant Prostate Cancer
|
| Kim Chi, MD, FRCPC
|
| Kim Chi presented an update on the utilization of PARP inhibitors at the 2019 Advanced Prostate Cancer Consensus Conference. Leading his presentation with the most recent positive phase III results from Lynparza® (olaparib), the only PARP inhibitor with positive phase III results in four different cancer types.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Recent Data From Conferences Worldwide
|
|
|
|
| Management of Men with PSA Recurrence or Persistence after Prostatectomy
|
| Christopher Evans, MD, FACS
|
| Christopher Evans discussed the management of men with PSA recurrence or persistence after radical prostatectomy. Dr. Evans started by highlighting that the AUA definition of biochemical recurrence is remission after prostatectomy defined as nadir PSA <0.2 ng/mL.
|
|
|
|
|
|
| PSMA Targeted Therapies
|
| Michael S. Hofman, MBBS (Hons), FRACP, FAANMS
|
| Michael Hofman presented prostate-specific membrane antigen (PSMA) targeted therapies during the Management of Castration-resistant Prostate Cancer (CRPC) session at the Advanced Prostate Cancer Consensus Conference, presenting data from both of his groups in Australia.
|
|
|
|
|
|
| Which Systemic Therapy for Which Patients with Newly Diagnosed Metastatic Prostate Cancer?
|
| Christopher Sweeney, MBBS
|
| Christopher Sweeney, discussed systemic therapy for prostate cancer. The spectrum of patients starting androgen deprivation therapy (ADT) for metastatic disease is quite vast. There are patients who present with de novo metastatic disease, and others who present after previous radical prostatectomy or radiotherapy.
|
|
|
|
|
|
| Immunotherapy for Metastatic Castrate Resistant Prostate Cancer
|
| Charles Drake, MD, Ph.D.
|
| Immunotherapy expert Charles Drake, MD, PhD, delivered a talk discussing immunotherapy for mCRPC at the management of CRPC session at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. The first major successful trial in immunotherapy for prostate cancer was the IMPACT trial in 2010. Sipuleucel-T was FDA approved based on results of the phase III IMPACT clinical trial.
|
|
|
|
|
|
| Pitfalls of PSMA PET-CT in Advanced Prostate Cancer Imaging
|
| Ian D. Davis, MBBS, PhD, FRACP, FAChPM
|
| Ian Davis, MBBS, PhD, FRACP, FAChPM, discussed some of the pitfalls and disadvantages of PSMA PET-CT in advanced prostate cancer imaging. Admitting that in his opinion, although 68Ga-PSMA PET-CT is great, there is a certain degree of false positives and negatives, inappropriate changes in management, and true positives that may not change management in today’s landscape.
|
|
|
|
|
|
|
